In brief, both preclinical and clinical studies have documented that chemotherapy, which is the treatment of choice for cancer patients, could not only induce skeletal muscle wasting, but it may also induce cardiac dysfunction in the form of reductions in LVEF, elevated cardiac troponin I, and decreased glutathione peroxidase. This evidence concerns the gene TNNI3 and cancer.